Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(1):68-76
In 2003 8 research centers in Russia from Ekaterinburg, Irkutsk, Krasnodar, Novosibirsk, Moscow, St. Petersburg and Smolensk took part in ARTEMIS Disk study 2003, the main purpose of which was the monitoring of resistance of the clinically significant yeast isolates to fluconazole and voriconazole using disk-diffusion method. A total of 1223 strains were tested. The main sources of clinical material were: genital (29%), upper respiratory tract (20%), lower gastrointestinal tract (16%), lower respiratory tract (13%) and urinary tract (9%). The predominant species were: C. albicans (73.7%), C. glabrata (5.2%), C. parapsilosis (3%) and C. krusei (2,8%). C. albicans remains leading causative agent of candidiasis and keeps high fluconazole susceptibility level (98.9% of strains susceptible). The lowest activity of fluconazole noted for C. krusei (6% of susceptible strains) and C. glabrata (61% of susceptible strains). Voriconazole is highly active against all Candida spp. including fluconazole-resistant strains (MIC50 and MIC90 for most strains were less then 0.1 and 0.5 mcg/ml, respectively).